Addition of Anlotinib Hydrochloride to the Stupp Regimen Versus the Stupp Regimen Alone for Newly Diagnosed Glioblastoma

Inclusion Criteria: * Newly diagnosed and histological proven glioblastoma * Complete gross resection or subtotal resection * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 * Adequate bone marrow, liver and renal function * Written informed consent Exclusion Criteria: * Meningeal carcinomatosis or spinal compression * Patients who have previously received chemotherapy, targeted therapy, or anti-angiogenesis * Active, known, or suspected autoimmune disease * Severe allergy to anlotinib or temozolomide * Patient having acute hepatitis virus infection, active tuberculosis, or other acute infectious diseases * Uncontrolled mental disorders * High risk of bleeding * Severe cardiovascular disease: myocardial ischemia or myocardial infarction above grade II, poorly controlled arrhythmias (including men with QTc interval ≥ 450 ms, women ≥ 470 ms), according to NYHA criteria; grades III to IV Insufficient function, or cardiac color Doppler ultrasound examination indicates left ventricular ejection fraction (LVEF) \<50% * Contraindicated for MRI examination * Recipient of live vaccine prior to the first dose of anlotinib * Ready for or previously received organ transplantation